Malaria vaccine fails to work after four years
A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday.
Medications
Mar 20, 2013 |
1 / 5 (1) |
0
Spin and bias in published studies of breast cancer trials
Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals of ...
Cancer
Jan 09, 2013 |
not rated yet |
0
|
Cancer drug improves survival in patients with metastatic melanoma
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients ...
Cancer
Nov 14, 2012 |
5 / 5 (2) |
0
|
Drug shrinks brain tumors in children with tuberous sclerosis complex
A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce a particular kind of brain tumor in patients with tuberous sclerosis complex (TSC)—a genetic disease ...
Cancer
Nov 13, 2012 |
not rated yet |
0
|
New MS drug proves effective where others have failed
A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' ...
Neuroscience
Oct 31, 2012 |
5 / 5 (1) |
0
Cannabis extract eases muscle stiffness typical of multiple sclerosis
Cannabis seems to ease the painful muscle stiffness typical of multiple sclerosis, indicate phase III trial results, published in the Journal of Neurology Neurosurgery and Psychiatry.
Neuroscience
Oct 09, 2012 |
5 / 5 (2) |
0
|
Golden age of prostate cancer treatment hailed as fourth drug in two years extends life
The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend ...
Cancer
Aug 15, 2012 |
1 / 5 (1) |
1
|
Denosumab superior to zoledronic acid for breast cancer patients with bone metastases
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, ...
Cancer
Aug 14, 2012 |
not rated yet |
0
|
Rejected drug may protect against toxic substance common to Alzheimer's and Parkinson's diseases
The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative ...
Neuroscience
Aug 13, 2012 |
not rated yet |
0
|
Rejected Alzheimer's drug shows new potential
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped ...
Psychology & Psychiatry
Jul 31, 2012 |
4 / 5 (1) |
1
|
Drug fails to curb heart bypass complications, but surgery gets safer
A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large, prospective study lead by ...
Cardiology
Jul 10, 2012 |
not rated yet |
0
|
Merck blood thinner shows mixed results: study
An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.
Cardiology
Mar 24, 2012 |
not rated yet |
0
New drug extends survival in patients with drug-resistant prostate cancer
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression ...
Cancer
Feb 01, 2012 |
5 / 5 (1) |
0
|
New antibody conjugate drug improves survival in older patients with acute myeloid leukaemia
(Medical Xpress)—Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to ...
Cancer
Nov 12, 2012 |
not rated yet |
0
Novel therapy helps ease pain and suffering for sickle cell patients
Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical ...
Diseases, Conditions, Syndromes
Sep 25, 2012 |
not rated yet |
0
